- Research article
- Open Access
Cytotoxicity of the methanol extracts of Elephantopus mollis, Kalanchoe crenata and 4 other Cameroonian medicinal plants towards human carcinoma cells
BMC Complementary and Alternative Medicine volume 17, Article number: 280 (2017)
Cancer still constitutes one of the major health concerns globally, causing serious threats on patients, their families, and the healthcare system.
In this study, the cytotoxicity of the methanol extract of Elephantopus mollis whole plant (EMW), Enantia chlorantha bark (ECB), Kalanchoe crenata leaves (KCL), Lophira alata bark (LAB), Millettia macrophylla leaves (MML) and Phragmanthera capitata leaves (PCL) towards five human solid cancer cell lines and normal CRL2120 fibroblasts, was evaluated. Extracts were subjected to qualitative chemical screening of their secondary metabolite contents using standard methods. The cytotoxicity of samples was evaluated using neutral red uptake (NR) assay meanwhile caspase activation was detected by caspase-Glo assay. Flow cytometry was used to analyze the cell cycle distribution and the mitochondrial membrane potential (MMP) whilst spectrophotometry was used to measure the levels of reactive oxygen species (ROS).
Phytochemical analysis revealed the presence of polyphenols, triterpenes and sterols in all extracts. The IC50 values of the best samples ranged from 3.29 μg/mL (towards DLD-1 colorectal adenocarcinoma cells) to 24.38 μg/mL (against small lung cancer A549 cells) for EMW, from 2.33 μg/mL (mesothelioma SPC212 cells) to 28.96 μg/mL (HepG2 hepatocarcinoma) for KCL, and from 0.04 μg/mL (towards SPC212 cells) to 0.55 μg/mL (towards A549 cells) for doxorubicin. EMW induced apoptosis in MCF-7 cells mediated by MMP loss and increased ROS production whilst KCL induced apoptosis via ROS production.
This study provides evidences of the cytotoxicity of the tested plant extract and highlights the good activity of Elephantopus mollis and Kalanchoe crenata. They deserve more exploration to develop novel cytotoxic drugs.
Cancer still constitutes a major health concern globally, causing serious threats on patients, their families, and the healthcare system. The related economic impact is significant and is increasing, with annual cost in 2010 being estimated at about 1.16 trillion US dollars . About 70% of deaths caused by cancer occur in low- and middle-income countries. Chemotherapy is recognized as the major mode of treatment of malignant diseases, and the plant kingdom has been the origin of many cytotoxic drugs such as paclitaxel (from Taxus brevifolia) and Vinca alkaloids (from Catharanthus roseus) [2,3,4,5]. The potential of African flora as a source of a variety of cytotoxic agents is intensively being demonstrated [6, 7]. In fact, various cytotoxic plants of the continent were reported amongst which are Anthocleista schweinfurthii, Morus mesozygia, Nauclea latifolia, Erythrina sigmoidea , Erythrina sacleuxii, Albizia gummifera, Strychnos usambarensis, Zanthoxylum gilletii, Bridelia micrantha, Croton sylvaticus, Albizia schimperiana, Erythrina burttii, Erythrina sacleuxii, Bridelia micarantha, Zanthoxylum giletii and Solanum aculeastrum . In our continuous search for cytotoxic agents from African flora, this study was undertaken to evaluate the antiproliferative activity of the methanol extracts of six Cameroonian plants used traditionally to treat cancers or disease states with symptoms related to cancer. These plants included Enantia chlorantha Oliv. (Annonaceae), Elephantopus mollis Kunth (Asteraceae), Kalanchoe crenata (Andrews) Haworth (Crassulaceae), Lophira alata Banks ex C.F.Gaertn.(Ochnaceae), Millettia macrophylla Benth. (Fabaceae) and Phragmanthera capitata (Spreng.) Balle (Loranthaceae). The study was extended to the assessment of the mode of action of the best extracts, namely those from Elephantopus mollis whole plant (EMW) and Kalanchoe crenata leaves (KCL).
Plant material and extraction
Plants studied in this work are used in the traditional medicine to treat cancer or disease states with symptoms related to cancer (Table 1). They were collected in different parts of Cameroon in February 2015 and included barks of Lophira alata and Enantia chlorantha, leaves of Phragmanthera capitata, Kalanchoe crenata and Millettia macrophylla and the whole plant of Elephantopus mollis. The identification of palnts was done by the Cameroon National Herbarium (HNC; Yaounde) and voucher specimens are availaible under accession numbers (Table 1). The powder obtained from each air dried plant sample (300 g) was macerated in methanol (MeOH, 1 L) for 48 h at room temperature. The macerate was further concentrated under reduced pressure to obtain the crude extract. All extracts were then conserved at 4 °C.
Various classes of secondary metabolites including anthraquinones (Borntrager’s test), alkaloids (Dragendorff’s and Mayer’s tests), coumarins (Lacton test), flavonoids (Aluminum chloride test), polyphenols (Ferric chloride test), saponins (Foam test), sterols (Salkowski’s test), triterpenes (Libermann Burchard’s test) and tannins (Gelatin test) were detected using described phytochemical methods [10,11,12,13].
The reference drug used in this work was doxorubicin 98.0%, purchased from Sigma-Aldrich (Munich, Germany).
Cell lines and culture
Five carcinoma and one normal cell lines were tested in this work. They were SPC212 human mesothelioma cell line obtained from American Type Culture Collection (ATCC) and provided by Dr. Asuman Demiroğlu Zergeroğlu (Gebze Technical University, Kocaeli, Turkey), A549 human non-small cell lung cancer (NSCLC) cell line, obtained from the Institute for Fermentation, Osaka (IFO, Japan) and provided by Prof. Dr. Tansu Koparal (Anadolu University, Eskisehir, Turkey), HepG2 hepatocarcinoma cells obtained from ATCC and MCF-7 breast adenocarcinoma cells obtained from ATCC and provided by Prof. Dr. Tansu Koparal (Anadolu University, Eskisehir, Turkey), DLD-1 colorectal adenocarcinoma cell lines obtained from ATCC and the normal CRL2120 human skin fibroblasts obtained from ATCC. The cells were maintained as a monolayer in DMEM medium (Sigma-aldrich, Munich, Germany), supplemented with 10% fetal calf serum and 1% penicillin (100 U/mL)-streptomycin (100 μg/mL) in a humidified 5% CO2 atmosphere at 37 °C.
Neutral red (NR) uptake assay
The cytotoxicity of samples was performed by the cheaper and sensitive NR uptake assay as previously described [14,15,16]. Samples were added in the culture medium so that dimethylsufoxide (DMSO) used prior for dilution, did not exceed 0.1% final concentration. Briefly, cells were detached by treatment with 0.25% trypsin/EDTA (Invitrogen, USA) and an aliquot of 1 × 104 cells was placed in each well of a 96-well cell culture plate (Thermo Scientific, Germany) in a total volume of 200 μL. The cells were allowed to attach overnight and subsequently treated with different concentrations of the extracts and doxorubicin. Each of the studied samples were immediately added in varying concentrations in additional 100 μL of culture medium to obtain a total volume of 200 μL/well. After 72 h incubation in humidified 5% CO2 atmosphere at 37 °C, the medium was removed and 200 μL fresh medium containing 50 μg/mL NR was added to each well and incubation continued for an additional 3 h at 37 °C in 5% CO2 atmosphere. The dye medium was then removed and each well was then washed rapidly with 200 μL phosphate buffer saline (PBS) followed by addition of 200 μL of acetic acid-water-ethanol in water (1:49:50). The plates were kept for 15 min at room temperature to extract the dye and then shaken for a few minutes on a GFL 3012 shaker (Gesellschaft für Labortechnik mbH, Burgwedel, Germany). Absorbance was measured on ELx 808 Ultra Microplate Reader (Biotek) equipped with a 540 nm filter. Each assay was done at least three times, with three replicates each. The viability was evaluated based on a comparison with untreated cells. The IC50 values represented the sample’s concentrations required to inhibit 50% of cell proliferation and were calculated from a calibration curve by linear regression using Microsoft Excel .
Flow cytometry for cell cycle analysis and detection of apoptotic cells
The cell-cycle analysis was performed by flow cytometry using BD cycletest™ Plus DNA Kit Assay (BD Biosciences, San Jose, USA). The BD Cycletest™ Plus DNA kit provides a set of reagents for isolating and staining cell nuclei. Flow cytometric analysis of differentially stained cells is used to estimate the DNA index (DI) and cell-cycle phase distributions. Briefly, MCF-7 cells (3 mL, 1 × 105 cells/mL) were seeded into each well of 6-well plates and allowed to attach for 24 h. The cells which were treated with ¼ × IC50, ½ × IC50 and IC50 concentrations of Elephantopus mollis whole plant (EMW) and Kalanchoe crenata leaves (KCL) extracts and the standard drug, doxorubicin, and grown for 72 h. The untreated cells (control) were also included in the assay. They were further trypsinized and suspended in 1 mL PBS, then centrifuged at 400 g for 5 min at room temperature (RT). The cells were further processed according to the manufacturer’s protocol . The cells were further measured on a BD FACS Aria I Cell Sorter Flow Cytometer (Becton-Dickinson, Germany). For each sample 104 cells were counted. For PI excitation, an argon-ion laser emitting at 488 nm was used. Cytographs were analyzed using BD FACSDiva™ Flow Cytometry Software Version 6.1.2 (Becton-Dickinson).
Caspase-Glo 3/7 and caspase-Glo 9 assay
Caspase activity in MCF-7 cells was detected using Caspase-Glo 3/7 and Caspase-Glo 9 Assay kits (Promega, Mannheim, Germany) as previously reported [18,19,20]. Cells were treated with EMW and KCL at their ½ × IC50 and IC50 values with DMSO as solvent control for 6 h. Luminescence was measured using an BioTek Synergy™ HT multi-detection microplate reader. Caspase activity was expressed as percentage of the untreated control.
Analysis of mitochondrial membrane potential (MMP)
The MMP was analyzed in MCF-7 cells by 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Biomol, Hamburg, Germany) staining as previously reported [18,19,20]. Cells (3 mL, 1 × 105 cells/mL) treated for 72 h with different concentrations (¼ × IC50, ½ × IC50 and IC50) of EMW, KCL and doxorubicin (drug control) or DMSO (solvent control) were incubated with JC-1 staining solution for 30 min according to the manufacturer’s protocol, as earlier reported. Subsequently, cells were measured in a BD FACS Aria I Cell Sorter Flow Cytometer (Becton-Dickinson, Germany). The JC-1 signal was measured at an excitation of 561 nm (150 mW) and detected using a 586/15 nm band-pass filter. The signal was analyzed at 640 nm excitation (40 mW) and detected using a 730/45 nm bandpass filter. Cytographs were analyzed using BD FACSDiva™ Flow Cytometry Software Version 6.1.2 (Becton-Dickinson). All experiments were performed at least in triplicates.
Measurement of reactive oxygen species (ROS)
The 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFH-DA) (Sigma-Aldrich) was used for the detection of ROS in MCF-7 cells treated with EMW, KCL and doxorubicin (drug control) or DMSO (solvent control) using OxiSelect™ Intracellular ROS Assay Kit (Green Fluorescence) as recommended by the manufacturer (Cell Biolabs Inc., San Diego, USA). This is a cell-based assay for measuring hydroxyl, peroxyl, or other reactive oxygen species activity within a cell. The assay employs the cell-permeable fluorogenic probe 2′,7′-dichlorodihydrofluorescin diacetate (DCFH-DA). DCFH-DA is diffused into cells and is deacetylated by cellular esterases to non-fluorescent 2′,7′-dichlorodihydrofluorescin (DCFH), which is rapidly oxidized to highly fluorescent 2′,7′-dichlorofluorescein (DCF) by ROS. Cells (1 × 104 cells) were treated with samples at ¼ × IC50, ½ × IC50 and IC50 for 24 h. After addition of 100 μL 1X DCFH-DA/DMEM solution to cells and incubation at 37 °C for 30–60 min, the fluorescence was measured using SpectraMax® M5 Microplate Reader (Molecular Devices, Biberach, Germany) at 480/530 nm. All experiments were performed at least in triplicates.
Phytochemical composition of plants’ extracts
Table 1 displays the chemical composition of the extracts and reveals the presence of polyphenols, triterpenes and sterols in all extracts. Coumarins, flavonoids, alkaloids, saponins and tannins were selectively distributed.
The results of the antiproliferative activity of the tested extracts and doxorubicin as determined by the NR uptake assay are shown in Table 2. The selectivity index (Table 2) was determined as the ratio of IC50 value in the CRL2120 normal fibroblast, divided by the IC50 in the cancer cell line. Extracts EMW, KCL and doxorubicin had IC50 values below 40 μg/mL in the five studied carcinoma cell lines. The IC50 values of PCL were not detected at up to 40 μg/mL in all cancer cell lines whilst ECB, LAB and MML showed selective activities. The recorded IC50 values ranged from 3.29 μg/mL (towards DLD-1 colorectal adenocarcinoma cells) to 24.38 (against small lung cancer A549 cells) for EMW, from 2.33 μg/mL (mesothelioma SPC212 cells) to 28.96 μg/mL (HepG2 hepatocarcinoma) for KCL, and from 0.04 μg/mL (towards SPC212 cells) to 0.55 μg/mL (towards A549 cells) for doxorubicin. All extracts including the two most active ones (EMW and KCL) were less toxic towards normal CRL2120 fibroblast than carcinoma cells (selectivity indexes above 1.00) (Table 2). The best extracts, EMW and KCL as well as doxorubicin were further tested for the effects on cell cycle distribution, caspases activity, MMP loss and ROS production in MCF-7 cells.
Cell cycle distribution in MCF-7 cells treated with EMM, KCL and doxorubicin is depicted in Fig. 1. EMW and KCL induced dose-dependent cell cycle modifications with progressive increase of sub-G0/G1 phase cells. Both EMW and KCL induced cell cycle arrest in G0/G1. Upon treatment of MCF-7 cells with the selected samples, they progressively underwent apoptosis; the increase of sub-G0/G1 cells ranged from 11.8% (¼ IC50) to 31% (IC50) for KCL, from 28.8% (¼ IC50) to 83.4% (IC50) for EMW, from 27.6% (¼ IC50) to 60% (IC50) for doxorubicin and only 3.1% in non-treated cells. Upon treatment of MCF-7 cells with EMW, KCL and doxorubicin with equivalent (eq.) to the ½ × IC50 and IC50 for 6 h, no activation of caspase 3/7 and caspase 9 activities was observed. MCF-7 cells were also treated with EMM, KCL and doxorubicin, and the integrity of the MMP was analyzed. Data shown in Fig. 2 indicate that treatments induced MMP loss, ranged from 33.9% at eq. to ¼ × IC50 to 90.1% at eq. to the IC50 for EMW, from 11.8% (¼ × IC50) to 19.7% (IC50) for KCL and 19.7% (¼ × IC50) to 26.6% (IC50) for doxorubicin. Upon treatment of MCF-7 cells with the selected at concentration eq. to ¼ × IC50, ½ × IC50 and IC50 values for 24 h, the production of ROS in cells was also analyzed (Fig. 3). EMW and KCL induced increased ROS levels of more than 3-folds (at IC50), as compared with non-treated cells whilst doxorubicin induced more than 2-folds increase.
Cancers appear as the leading cause of death globally, with 8.8 million deaths recorded in 2015. The most killing types are cancers of the lungs (1.69 million deaths), liver (788,000 deaths), colon (774,000 deaths), stomach (754,000 deaths) and breasts (571,000 deaths) . In this work, we assessed the ability of six medicinal plants used in cancer treatment or disease states with symptoms related to cancer, to prevent the proliferation of various carcinoma cell lines, including lung, liver, colon and breast cancers. These investigated cancer types are amongst the worldwide leading cause of cancer death [21, 22]. Botanicals displaying IC50 values below 20 μg/mL have been said to be good cytotoxic samples [7, 23, 24]. IC50 values below 20 μg/mL were recorded with EMW, KCL, MML and ECB respectively in 4, 3, 2 and 1 of the 5 tested carcinoma cells. Importantly, IC50 values below 5 μg/mL were obtained with EMW in 4/5 carcinoma cell lines as well as KCL towards SPC212 cells and MML against HepG2 cells. These data highlight the usefulness of these extracts in the fight against solid cancers. This hypothesis is strengthened by the good selectivity index (SI > 1; Table 2) of the tested extract, which is compatible with their possible use in cancer chemotherapy.
Elephantopus mollis and Millettia macrophylla are traditionally used in the treatment of cancers [25, 26]. The two plants, Especiallye. mollis, had cytotoxic effects on the tested carcinoma cells, validating their traditional use in the management of malignancies. In this study, plants used traditionally to treat disease states with symptoms related to cancer, were Lophira alata, Enantia chlorantha, Phragmanthera capitata and Kalanchoe crenata. Amongst them, only P. capitata was not active on the tested cancer cell lines. This also consolidates the recommandations that ethnopharmacological usages such as immune and skin disorders, inflammatory, infectious, parasitic and viral diseases should be taken into account when selecting plants that treat cancer .
To the best of our knowledge, the anticancer activity of Enantia chlorantha, Lophira alata and Kalanchoe crenata is being reported herein for the first time. The antiproliferative effect of ethyl acetate extract of Elephantopus mollis, collected from Penang Agriculture Department, Relau, Malaysia), on HepG2 cells, with the lowest IC50 value of 9.38 μg/mL, NCI-H23 cells (13.17 μg/mL), T-47D cells (12.57 μg/mL) and Caov-3 cells (42.11 μg/mL) [25, 28], was reported. A much more lower IC50 value of 3.74 μg/mL was obtained with samples from Cameroon. This could be explained by possible geographic variations in the chemical constitution of the plant. However, both studies confirm the cytotoxic potential of this plant. The cytotoxicity of methanolic extract and chalcone dimers from L. alata on Ehrlich Ascites carcinoma cells  was also reported in the present work. This plant was moderately active against HepG2 cells, providing additional information on the anticancer activity of the plant. The poor cytotoxic effects of compounds and phenolic fractions of M. macrophylla towards breast cancer cells MCF-7 and MDA-MB-231, was reported . Data obtained herein are in accordance with this previous study, as a moderate effect of MML was obtained in MCF-7 cells. However, MML had good effect against SPC212 lung adenocarcinoma and HepG2 adenocarcinoma cells, highlighting its possible use in the fight against cancers.
Finally, evidences of the antiproliferative effects of the tested plant extract, highlights the good activity of Elephantopus mollis, Kalanchoe crenata and in lesser extent Millettia macrophylla have been provided. Extract of E. mollis, induced apoptosis in MCF-7 cells, mediated by MMP loss and increased ROS production whilst Kalanchoe crenata leaves extract induced apoptosis via ROS production (Figs. 2 and 3). It should be noted that only ROS production is not enough to identify cell apoptosis. Therefore, additional studies including detection of other molecules related to apoptosis such as BCL2, BAX, PRPP, etc., will be performed. Purification of the most active plants (Elephantopus mollis, Kalanchoe crenata and Millettia macrophylla) will also be performed to identify their cytotoxic constituents.
In this work, the antiproliferative activity of extracts from six Cameroonian medicinal plants, Lophira alata, Enantia chlorantha, Phragmanthera capitata, Kalanchoe crenata, Elephantopus mollis and Millettia macrophylla was reported on five human solid cancer cell lines and normal CRL2120 fibroblasts. The three most active extracts were those from E. mollis whole plant, K. crenata leaves and M. macrophylla leaves. They can be used in the management of malignant diseases and deserve more exploration to isolate their active constituents in order to develop novel cytotoxic drugs.
American Type Culture Collection
Bcl-2-associated X protein
B-cell lymphoma 2
Dulbecco’s Modified Eagle Medium
Enantia chlorantha bark extract
Elephantopus mollis extract
Cameroon National Herbarium
Kalanchoe crenata leaves extract
Lophira alata bark extract
Millettia macrophylla leaves extract
Mitochondrial membrane potential
Phosphate buffer saline
Phragmanthera capitata leaves extract
Reactive oxygen species
Stewart BW, Wild CP. In: IAfRo C, editor. World cancer report 2014. Lyon; 2014.
Omosa LK, Midiwo JO, Masila VM, Gisacho BM, Munayi R, Francisca K, et al. Cytotoxicity of 91 Kenyan indigenous medicinal plants towards human CCRF-CEM leukemia cells. J Ethnopharmacol. 2016;179:177–96.
Stevigny C, Bailly C, Quetin-Leclercq J. Cytotoxic and antitumor potentialities of aporphinoid alkaloids. Curr Med Chem Anticancer Agents. 2005;5(2):173–82.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461–77.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–35.
Kuete V, Efferth T. Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy. J Ethnopharmacol. 2011;137(1):752–66.
Kuete V, Efferth T. African flora has the potential to fight multidrug resistance of cancer. Biomed Res Int. 2015;2015:914813.
Kuete V, Djeussi DE, Mbaveng AT, Zeino M, Efferth T. Cytotoxicity of 15 Cameroonian medicinal plants against drug sensitive and multi-drug resistant cancer cells. J Ethnopharmacol. 2016;186:196–204.
Omosa LK, Midiwo JO, Masila VM, Gisacho BM, Munayi R, Francisca K, et al. Cytotoxicity of 91 Kenyan indigenous medicinal plants towards human CCRF-CEM leukemia cells. J Ethnopharmacol. 2015;179:177–96.
Harbone J (ed.): Phytochemical methods: a guide to modern techniques of plant analysis. London: Chapman & Hall; 1973.
Ngameni B, Fotso GW, Kamga J, Ambassa P, Abdou T, Fankam AG, Voukeng IK, Ngadjui BT, Abegaz BM, Kuete V. 9 - Flavonoids and related compounds from the medicinal plants of Africa. In: Medicinal Plant Research in Africa. edn. Edited by Kuete V. Oxford: Elsevier; 2013: 301–350.
Wansi JD, Devkota KP, Tshikalange E, Kuete V. 14 - Alkaloids from the Medicinal Plants of Africa. In: Medicinal Plant Research in Africa. edn. Edited by Kuete V. Oxford: Elsevier; 2013: 557–605.
Poumale HMP, Hamm R, Zang Y, Shiono Y, Kuete V. 8 - Coumarins and Related Compounds from the Medicinal Plants of Africa. In: Medicinal Plant Research in Africa. edn. Edited by Kuete V. Oxford: Elsevier; 2013: 261–300.
Borenfreund E, Babich H, Martin-Alguacil N. Comparisons of two in vitro cytotoxicity assays-the neutral red (NR) and tetrazolium MTT tests. Toxicol in Vitro. 1988;2(1):1–6.
Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008;3(7):1125–31.
Kuete V, Omosa LK, Tala VR, Midiwo JO, Mbaveng AT, Swaleh S, et al. Cytotoxicity of plumbagin, rapanone and 12 other naturally occurring quinones from Kenyan flora towards human carcinoma cells. BMC Pharmacol Toxicol. 2016;17(1):60.
Kuete V, Krusche B, Youns M, Voukeng I, Fankam AG, Tankeo S, et al. Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts. J Ethnopharmacol. 2011;134(3):803–12.
Kuete V, Sandjo L, Nantchouang Ouete J, Fouotsa H, Wiench B, Efferth T. Cytotoxicity and modes of action of three naturally occuring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. Phytomedicine. 2013;21(3):315–22.
Kuete V, Fankam AG, Wiench B, Efferth T. Cytotoxicity and modes of action of the methanol extracts of six Cameroonian medicinal plants against multidrug-mesistant tumor cells. Evid Based Complement Alternat Med. 2013;2013:285903.
Kuete V, Tankeo SB, Saeed ME, Wiench B, Tane P, Efferth T. Cytotoxicity and modes of action of five Cameroonian medicinal plants against multi-factorial drug resistance of tumor cells. J Ethnopharmacol. 2014;153(1):207–19.
WHO: http://www.who.int/mediacentre/factsheets/fs297/en/. 2017. Accessed on February 12, 2017.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
Boik J. Natural compounds in cancer therapy. Minnesota USA: Oregon Medical Press; 2001.
Brahemi G, Kona FR, Fiasella A, Buac D, Soukupova J, Brancale A, et al. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. J Med Chem. 2010;53(7):2757–65.
Ooi KL, Tengku Muhammad TS, Lam LY, Sulaiman SF. Cytotoxic and apoptotic effects of ethyl acetate extract of Elephantopus mollis Kunth. In human liver carcinoma HepG2 cells through caspase-3 activation. Integr Cancer Ther. 2014;13(3):NP1–9.
Zingue S, Tchoumtchoua J, Ntsa DM, Sandjo LP, Cisilotto J, Nde CB, et al. Estrogenic and cytotoxic potentials of compounds isolated from Millettia macrophylla Benth (Fabaceae): towards a better understanding of its underlying mechanisms. BMC Complement Altern Med. 2016;16(1):421.
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.
Daisy P, Jasmine R, Ignacimuthu S, Murugan E. A novel steroid from Elephantopus scaber L. an ethnomedicinal plant with antidiabetic activity. Phytomedicine. 2009;16(2–3):252–7.
Ajiboye TO, Yakubu MT, Oladiji AT. Cytotoxic, antimutagenic, and antioxidant activities of methanolic extract and chalcone dimers (lophirones B and C) derived from Lophira alata (van Tiegh. Ex Keay) stem bark. J Evid Based Complementary Altern Med. 2014;19(1):20–30.
Adjanohoun J, Aboubakar N, Dramane K, Ebot M, Ekpere J, Enow-Orock E, et al. Traditional medicine and pharmacopoeia: contribution to ethnobotanical and floristic studies in Cameroon. OUA/STRC: Lagos; 1996.
Adebiyi OE, Abatan MO. Phytochemical and acute toxicity of ethanolic extract of Enantia chlorantha (oliv) stem bark in albino rats. Interdiscip Toxicol. 2013;6(3):145–51.
Agbaje EO, Onabanjo AO. Toxicological study of the extracts of antimalarial medicinal plant Enantia chlorantha. Cent Afr J Med. 1994;40:71–3.
Adesokan AA, Akanji MA, Yakubu MT. Antibacterial potentials of aqueous extract of Enantia chlorantha stem bark. Afr J Biotechnol. 2007;6:2502–5.
Ooi KL, Muhammad TS, Tan ML, Sulaiman SF. Cytotoxic, apoptotic and anti-alpha-glucosidase activities of 3,4-di-O-caffeoyl quinic acid, an antioxidant isolated from the polyphenolic-rich extract of Elephantopus mollis Kunth. J Ethnopharmacol. 2011;135(3):685–95.
Kamgang R, Foyet AF, Essame JL, Ngogang JY. Effect of methanolic fraction of Kalanchoe crenata on metabolic parameters in adriamycin-induced renal impairment in rats. Indian J Pharmacol. 2012;44(5):566–70.
Akinsulire OR, Aibinu IE, Adenipekun T, Adelowotan T, Odugbemi T. In vitro antimicrobial activity of crude extracts from plants Bryophyllum pinnatum and Kalanchoe crenata. Afr J Tradit Complement Altern Med. 2007;4(3):338–44.
Kamgang R, Mboumi RY, Fondjo AF, Tagne MA, N'Dille GP, Yonkeu JN. Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (Crassulaceae). J Nat Med. 2008;62(1):34–40.
Nguelefack TB, Nana P, Atsamo AD, Dimo T, Watcho P, Dongmo AB, et al. Analgesic and anticonvulsant effects of extracts from the leaves of Kalanchoe crenata (Andrews) Haworth (Crassulaceae). J Ethnopharmacol. 2006;106(1):70–5.
Falade MO, Akinboye DO, Gbotosho GO, Ajaiyeoba EO, Happi TC, Abiodun OO, et al. In vitro and in vivo antimalarial activity of Ficus thonningii Blume (Moraceae) and Lophira alata banks (Ochnaceae), identified from the ethnomedicine of the Nigerian Middle Belt. J Parasitol Res. 2014;2014:972853.
Murakami A, Tanaka S, Ohigashi H, Hirota M, Irie R, Takeda N, et al. Chalcone tetramers, lophirachalcone and alatachalcone, from Lophira alata as possible anti-tumor promoters. Biosci Biotechnol Biochem. 1992;56(5):769–72.
Tih AE, Ghogomu RT, Sondengam BL, Caux C, Bodo B. minor Biflavonoids from Lophira alata leaves. J Nat Prod. 2006;69(8):1206–8.
Abderamane B, Tih AE, Ghogomu RT, Blond A, Bodo B. Isoflavonoid derivatives from Lophira alata stem heartwood. Z Naturforsch C. 2011;66(3–4):87–92.
Lenta BN, Ateba JT, Chouna JR, Aminake MN, Nardella F, Pradel G, et al. Two 2,6-Dioxabicyclo[3.3.1]nonan-3-ones from Phragmanthera capitata (Spreng.) Balle (Loranthaceae). Helvet Chim Acta. 2015;98(7):945–52.
Galani BR, Sahuc ME, Njayou FN, Deloison G, Mkounga P, Feudjou WF, et al. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front Microbiol. 2015;6:488.
Kuete V, Efferth T. Cameroonian medicinal plants: pharmacology and derived natural products. Front Pharmacol. 2010;1:123.
V.K and H.S. are thankful to Scientific and Technological Research Council of Turkey (TÜBİTAK) for 6 months travel grant (to V.K.) and to Scientific Research Projects Commission of Anadolu University, Eskisehir, Turkey for the funding grant 1507F563 (to V.K. and H.S.). A grant for part of this work was also provided by International Science Programme, Uppsala University, Sweden (ISP)-KEN-02 project. Authors are thankful to Şennur Görgülü for FACS measurements.
Availability of data and materials
The datasets supporting the conclusions of this article are presented in this main paper.
VK, FWF and OK carried out the experiments; VK wrote the manuscript. VK, VPB and HS designed the experiments; HS supervised the work, provided the facilities for the study. All authors read the manuscript and approved the final version.
The authors declare that they have no competing interests.
Consent for publication
Not applicable in this section.
Ethic approval and consent to participate
Not applicable in this section.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kuete, V., Fokou, F.W., Karaosmanoğlu, O. et al. Cytotoxicity of the methanol extracts of Elephantopus mollis, Kalanchoe crenata and 4 other Cameroonian medicinal plants towards human carcinoma cells. BMC Complement Altern Med 17, 280 (2017). https://doi.org/10.1186/s12906-017-1793-1
- Elephantopus mollis
- Kalanchoe crenata
- Mode of action